利伐沙班与低分子量肝素钙治疗恶性肿瘤合并静脉血栓栓塞症的疗效对比  

Efficacy comparison of rivaroxaban and low molecular weight heparin in the treatment of malignant tumors with venous thromboembolism

作　　者：田爱军 王朝霞 TIAN Ai-jun;WANG Zhao-xia(Gaomi People's Hospital,Weifang 261500,China)

机构地区：[1]高密市人民医院,261500

出　　处：《中国实用医药》2024年第20期114-117,共4页China Practical Medicine

摘　　要：目的对比利伐沙班与低分子量肝素钙治疗恶性肿瘤合并静脉血栓栓塞症的疗效。方法择取68例恶性肿瘤合并静脉血栓栓塞症患者,利用随机数字表分为对照组和观察组,每组34例。对照组采用低分子量肝素钙治疗,观察组实施利伐沙班治疗。对比两组凝血功能指标、临床疗效及随访相关情况。结果治疗后,观察组的凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、D-二聚体(D-D)、纤维蛋白原(FIB)、国际标准化比值(INR)分别为(16.90±1.29)s、(12.18±1.51)s、(27.77±4.54)s、(1.08±0.30)mg/L、(3.82±0.68)g/L、INR(0.99±0.11),与对照组的(16.52±1.18)s、(12.13±1.45)s、(28.60±4.67)s、(1.12±0.33)mg/L、(3.90±0.79)g/L、INR(0.97±0.08)对比差异不大(P>0.05)。观察组总有效率为91.18%,出血事件发生率为8.82%,复发率为11.76%,死亡率为2.94%,与对照组的88.24%、11.76%、14.71%、5.88%对比差异不大(P>0.05)。结论对恶性肿瘤合并静脉血栓栓塞症患者采用利伐沙班、低分子量肝素钙治疗均可取得较好的效果且安全性相当,临床可根据患者具体情况选择用药。Objective To compare the efficacy of rivaroxaban and low molecular weight heparin in the treatment of malignant tumors with venous thromboembolism.Methods 68 patients with malignant tumors and venous thromboembolism were selected,and were divide into a control group and an observation group using a random number table,each with 34 cases.The control group was treated with low molecular weight heparin,while the observation group was treated with rivaroxaban.The coagulation function indicators,clinical efficacy,and follow-up related information were compared between the two groups.Results After treatment,the thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT),D-dimer(D-D),fibrinogen(FIB)and international normalized ratio(INR)of the observation group were(16.90±1.29)s,(12.18±1.51)s,(27.77±4.54)s,(1.08±0.30)mg/L,(3.82±0.68)g/L,and(0.99±0.11),while those of the control group were(16.52±1.18)s,(12.13±1.45)s,(28.60±4.67)s,(1.12±0.33)mg/L,(3.90±0.79)g/L,and(0.97±0.08),and there was no significant difference between the two groups(P>0.05).The total effective rate of the observation group was 91.18%,the incidence of bleeding events was 8.82%,the recurrence rate was 11.76%,and the mortality rate was 2.94%,which had little difference compared with 88.24%,11.76%,14.71%,and 5.88%of the control group(P>0.05).Conclusion For the treatment of malignant tumors combined with venous thromboembolism,both rivaroxaban and low molecular weight heparin can achieve good results and are equally safe.Clinically,medication can be selected based on the specific situation of the patient.

关 键 词：恶性肿瘤 静脉血栓栓塞症 利伐沙班 低分子量肝素钙 

分 类 号：R730.5[医药卫生—肿瘤]